CY1112562T1 - Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης - Google Patents

Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης

Info

Publication number
CY1112562T1
CY1112562T1 CY20111100759T CY111100759T CY1112562T1 CY 1112562 T1 CY1112562 T1 CY 1112562T1 CY 20111100759 T CY20111100759 T CY 20111100759T CY 111100759 T CY111100759 T CY 111100759T CY 1112562 T1 CY1112562 T1 CY 1112562T1
Authority
CY
Cyprus
Prior art keywords
pharmaceutical compositions
oral administration
pharmaceutically active
kalsitonin
agent
Prior art date
Application number
CY20111100759T
Other languages
English (en)
Inventor
Joseph M Ault
Moise Azria
Simon David Bateman
Joseph Sikora
Gregory Sparta
Rebecca Fai-Ying Yang
Jie Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1112562T1 publication Critical patent/CY1112562T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Στο παρόν περιέχονται στερεές φαρμακευτικές συνθέσεις κατάλληλες για τη στοματική χορήγηση φαρμακευτικά ενεργών παραγόντων, π.χ. πεπτιδίων, που περιλαμβάνουν μια θεραπευτικά αποτελεσματική ποσότητα ενός φαρμακευτικά ενεργού παράγοντα ˙ μια κροσποβιδόνη ή ποβιδόνη ˙ και έναν παράγοντα χορήγησης του εν λόγω φαρμακευτικά ενεργού παράγοντα. Οι συνθέσεις παρέχουν εξαίρετη στοματική βιοδιαθεσιμότητα φαρμακευτικά ενεργών παραγόντων, και ιδίως της καλσιτονίνης.
CY20111100759T 2000-12-06 2011-08-09 Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης CY1112562T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06
EP01985368A EP1341526B1 (en) 2000-12-06 2001-12-05 Pharmaceutical compositions for the oral delivery of calcitonin

Publications (1)

Publication Number Publication Date
CY1112562T1 true CY1112562T1 (el) 2016-02-10

Family

ID=22953160

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100759T CY1112562T1 (el) 2000-12-06 2011-08-09 Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης

Country Status (27)

Country Link
US (1) US7049283B2 (el)
EP (1) EP1341526B1 (el)
JP (2) JP4898078B2 (el)
KR (1) KR100847695B1 (el)
CN (1) CN1304048C (el)
AT (1) ATE513541T1 (el)
AU (2) AU3454702A (el)
BR (2) BR0115965A (el)
CA (1) CA2436599C (el)
CY (1) CY1112562T1 (el)
CZ (1) CZ305418B6 (el)
DK (1) DK1341526T3 (el)
EC (1) ECSP034639A (el)
ES (1) ES2367009T3 (el)
HK (1) HK1059565A1 (el)
HU (1) HU230632B1 (el)
IL (2) IL155992A0 (el)
MX (1) MXPA03005096A (el)
NO (1) NO332936B1 (el)
NZ (1) NZ526196A (el)
PL (1) PL209703B1 (el)
PT (1) PT1341526E (el)
RU (1) RU2287999C2 (el)
SI (1) SI1341526T1 (el)
SK (1) SK287613B6 (el)
WO (1) WO2002045754A2 (el)
ZA (1) ZA200304295B (el)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4588221B2 (ja) * 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物
PT1397156E (pt) * 2001-06-01 2007-05-31 Novartis Ag Método para a administração oral da hormona paratireóide ( pth ).
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
ATE534381T1 (de) * 2003-03-17 2011-12-15 Japan Tobacco Inc Pharmazeutische cetp-inhibitor-zusammensetzungen
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
US20070065505A1 (en) * 2003-07-11 2007-03-22 Shoufeng Li Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
CA2536487C (en) * 2003-09-12 2011-10-25 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
JP4885856B2 (ja) * 2004-05-19 2012-02-29 エミスフェアー・テクノロジーズ・インク 局所クロモリン製剤
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
JP5175553B2 (ja) * 2005-02-01 2013-04-03 エミスフェアー・テクノロジーズ・インク 胃内滞留および制御放出型送達系
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
US8026392B2 (en) 2005-09-19 2011-09-27 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-Chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
KR20140053419A (ko) * 2005-11-17 2014-05-07 노파르티스 아게 약제학적 조성물
US7476405B2 (en) * 2006-02-23 2009-01-13 Iomedix Sleep International Srl Compositions and methods for the induction and maintenance of quality sleep
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
CN101557827A (zh) * 2006-08-31 2009-10-14 诺瓦提斯公司 用于口服递送的包含hgh的药物组合物
CA2572004A1 (en) * 2006-12-08 2008-06-08 Bernard Charles Sherman Tablets comprising entacapone and crospovidone
KR20150091536A (ko) * 2007-03-02 2015-08-11 노파르티스 아게 칼시토닌의 경구 투여
RU2469728C2 (ru) 2007-11-02 2012-12-20 Эмисфире Текнолоджис, Инк. Способ лечения дефицита витамина b12
EP3741359A1 (en) * 2008-08-18 2020-11-25 Entera Bio Ltd. Methods and compositions for oral administration of proteins
CA2755068C (en) * 2009-03-12 2018-11-06 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
JP5865903B2 (ja) * 2010-06-09 2016-02-17 エミスフェアー・テクノロジーズ・インク 経口鉄欠乏療法
JP5902194B2 (ja) 2010-12-16 2016-04-13 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストとｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩とを含む固形組成物
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
EP4331667A3 (en) 2012-03-22 2024-05-08 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HRP20231060T1 (hr) 2012-03-22 2023-12-22 Novo Nordisk A/S Pripravci peptida glp-1 i njihova priprava
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
BR112017022857B1 (pt) * 2015-07-08 2023-09-26 Research & Business Foundation Sungkyunkwan University Composto, método para preparar o composto, uso de uma composição
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (zh) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 一种用于口服给药的固体快速释放布南色林片及其制备方法
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (it) 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) * 1991-06-25 1993-01-08 Pioneer Electron Corp 光記録媒体
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
AU4353996A (en) 1994-12-14 1996-07-03 Bioglan Ireland (R & D) Limited Pharmaceutical tablet formulations for direct compression
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ES2263428T3 (es) 1997-02-07 2006-12-16 Emisphere Technologies, Inc. Compuesto y composicion para agentes activos de administracion.
KR100620338B1 (ko) 1998-03-16 2006-09-13 넥타르 테라퓨틱스 에어로졸형 활성 제제 전달 방법
WO2000057857A1 (en) 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
AU4218400A (en) * 1999-04-05 2000-10-23 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making
JP4588221B2 (ja) * 1999-04-05 2010-11-24 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための二ナトリウム塩、一水和物、およびエタノール溶媒和物

Also Published As

Publication number Publication date
WO2002045754A3 (en) 2003-01-03
PL209703B1 (pl) 2011-10-31
SK287613B6 (sk) 2011-04-05
KR20040018309A (ko) 2004-03-03
US7049283B2 (en) 2006-05-23
HUP0302319A3 (en) 2013-04-29
ATE513541T1 (de) 2011-07-15
MXPA03005096A (es) 2003-09-05
IL155992A0 (en) 2003-12-23
CZ20031566A3 (cs) 2003-09-17
ECSP034639A (es) 2003-07-25
JP2009185052A (ja) 2009-08-20
WO2002045754A2 (en) 2002-06-13
CN1479612A (zh) 2004-03-03
CN1304048C (zh) 2007-03-14
JP2004515480A (ja) 2004-05-27
PL362247A1 (en) 2004-10-18
AU3454702A (en) 2002-06-18
JP4898078B2 (ja) 2012-03-14
NO20032511L (no) 2003-06-03
RU2287999C2 (ru) 2006-11-27
HU230632B1 (hu) 2017-05-29
CZ305418B6 (cs) 2015-09-09
PT1341526E (pt) 2011-09-01
DK1341526T3 (da) 2011-10-03
SI1341526T1 (sl) 2011-10-28
AU2002234547B2 (en) 2005-03-24
SK6882003A3 (en) 2004-01-08
CA2436599A1 (en) 2002-06-13
IL155992A (en) 2008-04-13
CA2436599C (en) 2011-01-25
ES2367009T3 (es) 2011-10-27
KR100847695B1 (ko) 2008-07-23
EP1341526B1 (en) 2011-06-22
BR0115965A (pt) 2003-10-28
HUP0302319A2 (hu) 2003-11-28
HK1059565A1 (en) 2004-07-09
BRPI0115965B1 (pt) 2017-09-26
NZ526196A (en) 2005-01-28
NO20032511D0 (no) 2003-06-03
ZA200304295B (en) 2004-05-10
NO332936B1 (no) 2013-02-04
EP1341526A2 (en) 2003-09-10
US20020123459A1 (en) 2002-09-05

Similar Documents

Publication Publication Date Title
CY1112562T1 (el) Φαρμακευτικες συνθεσεις για τη στοματικη χορηγηση της καλσιτονινης
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
ATE291898T1 (de) Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
DK1156790T3 (da) Kombinationer af formoterol og motetason furat
DE60143393D1 (de) Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
CY1106072T1 (el) Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος
ID27504A (id) Formulasi oral baru
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
CY1115386T1 (el) Συνδυασμος αζελαστινης και μομεταζονης
ATE235895T1 (de) Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis
CY1105648T1 (el) Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης
DK1257254T3 (da) Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom
HK1089950A1 (en) Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form
CY1105211T1 (el) Φαρμακευτικοι συνδυασμοι που πepιλαμβανουν εναν ανταγωνιστη του υποδοχεα p2τ και μελαγατρανη
ATE286716T1 (de) Pharmazeutische formulierungen enthaltend salmeterol
PA8531801A1 (es) Formulaciones estabilizadas que comprenden composiciones hidroliticamente inestables